Skip to main content
. 2024 Sep 17;19(9):e0310170. doi: 10.1371/journal.pone.0310170

Table 2. Subject characteristics.

Placebo (n = 22) TrigozimR (n = 73) 600 mg (n = 21) 1200 mg (n = 25) 1800 mg (n = 27)
Median min, max Median min, max Median min, max Median min, max Median min, max
Age (years) 54 [40,68] 51 [40,75] 53 [40,75] 51 [40,72] 51 [40,72]
Height (meters) 181 [175,190] 180 [170,197] 181 [170,194] 178 [173,195] 180 [172,197]
Weight (kg) 85 [65,122] 85 [67,160] 85 [72,160] 80,5 [68,125] 87 [67,130]
Body mass index (kg/m2) 25,5 [21.2,35.6] 25,9 [20.8,42.5] 25,8 [21.4,42.5] 25,0 [20.8,36.1] 26,0 [21.3,33.8]
Stimulantia (1 = yes, 2 = no) 2 [1,2] 2 [1,2] 2 [1,2] 2 [1,2] 2 [1,2]
Tobacco (units per day) 0 [0,15] 0 [0,25] 0 [0,12] 0 [0,16] 0 [0,25]
Alcohol (units per day) 2 [0,12] 3 [0,14] 3 [0,14] 3 [0,10] 4 [0,14]